NSD2降解剂纠正t(4;14)多发性骨髓瘤的致癌染色质景观
本研究报道了靶向NSD2的配体导向降解剂(NSD2-LDD),其通过cereblon招募并经PWWP1介导,选择性清除全长及含PWWP1结构域的NSD2蛋白异构体。NSD2-LDD处理导致H3K36me2全局丢失,引起H3K27me3向启动子近端扩散并重塑顺式调控互作,从而逆转t(4;14)转录程序,抑制骨髓瘤疾病相关表型;在细胞系异种移植和基因工程小鼠模型中延长中位生存期,但反应仅限于含PWWP1的模型。
要点
- NSD2-LDD选择性降解全长及含PWWP1的NSD2异构体,诱导H3K36me2全局丢失。
- 降解NSD2可逆转t(4;14)转录程序并抑制骨髓瘤细胞黏附、3D集落生长及旁分泌信号。
- 在t(4;14)模型中NSD2-LDD延长中位生存期,但疗效仅限于含PWWP1的模型。
核心结论
- NSD2是可成药的依赖靶点,支持将NSD2降解作为高危多发性骨髓瘤的新型靶向治疗策略进行临床开发。
研究设计与样本
- 研究报道了NSD2-LDD的发现,并整合患者单细胞图谱、模型3D表观基因组和空间转录组学进行分析。
- 在细胞系来源异种移植和t(4;14)基因工程小鼠模型中评估了NSD2-LDD的体内疗效。
主要发现
- NSD2-LDD选择性且强效地清除全长及含PWWP1结构域的NSD2蛋白异构体。
- NSD2-LDD处理诱导H3K36me2全局丢失,导致H3K27me3向启动子近端扩散并重塑顺式调控互作,逆转t(4;14)转录程序。
- NSD2降解抑制骨髓瘤疾病相关表型,包括基质黏附、3D集落生长和旁分泌信号。
- 在细胞系来源异种移植和t(4;14)基因工程小鼠模型中,NSD2-LDD延长中位生存期,伴随肿瘤H3K36me2丢失和微环境重塑。
临床怎么用
- NSD2降解策略可能适用于含PWWP1结构域的t(4;14)多发性骨髓瘤患者,需进一步临床验证。
局限性
- NSD2-LDD的反应仅限于含PWWP1的模型,不适用于所有t(4;14)多发性骨髓瘤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The t(4;14) chromosomal translocation drives overexpression of the histone methyltransferase NSD2 and defines a high-risk segment of patients with multiple myeloma (MM). Herein, we report the discovery of NSD2-ligand-directed degrader (NSD2-LDD), a cereblon-recruiting and PWWP1-mediated LDD that selectively and potently eliminates full-length and PWWP1 domain-containing NSD2 protein isoforms. NSD2-LDD treatment induces the global loss of H3K36me2, leading to promoter-proximal spreading of H3K27me3 and rewiring of cis-regulatory interactions that reverse t(4;14) transcriptional programs. These effects suppress MM disease-associated phenotypes, including stromal adhesion, 3-dimensional (3D) colony growth, and paracrine signaling. By integrating patient single-cell profiles with model 3D epigenomic and spatial transcriptomics, we delineate t(4;14) disease state together with the tumor-intrinsic reprogramming and resultant remodeling of the bone marrow microenvironment upon NSD2 degradation. In cell line-derived xenografts and genetically engineered mouse models of t(4;14), NSD2-LDD extends median survival, accompanied by tumoral H3K36me2 loss and niche remodeling. Although the NSD2-LDD response is restricted to PWWP1-containing models, collectively this work validates NSD2 as a tractable dependency and supports the clinical development of NSD2 degradation as a novel, targeted therapeutic strategy in high-risk MM.
引用
- Hu B, Edwards JT, Modi H, et al. NSD2 degradation remediates the oncogenic cistrome in t(4;14) multiple myeloma. Blood. 2026. PMID: 42371798. doi:10.1182/blood.2025031998
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。